News Room

Media Contact: media@principiabio.com

09.18.17

Principia Biopharma Presents Late-Breaking Interim Phase 2 Data of PRN1008 in Pemphigus at European Academy of Dermatology and Venereology Meeting 

07.11.17

Principia Biopharma Announces PRN1008 Receives Orphan Drug Designation From FDA For Treatment of Pemphigus Vulgaris

06.13.17

AbbVie and Principia Announce Collaboration on Oral Immunoproteasome Inhibitors

06.06.16

Principia Biopharma Announces Presentation of Initial Clinical Data on PRN1371 at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

01.07.16

Principia Biopharma Advances BTK Inhibitor Program in Autoimmune Disease and FGFR Inhibitor Program in Oncology

06.15.15

Principia Biopharma Presents Full Phase 1 Clinical Trial Results For PRN1008, A Novel Reversible Covalent BTK Inhibitor, Supporting Further Clinical Development in Autoimmune and Inflammatory Diseases

05.26.15

Principia Biopharma and UCSF Scientists Announce Publication of Seminal Paper on Reversible Covalent Drugs in Nature Chemical Biology

01.12.15

Principia Biopharma Appoints Roy Hardiman As Chief Business Officer And Lewis Shuster To Board Of Directors

01.08.15

Principia Biopharma Successfully Completes Phase 1 Clinical Trial Of PRN1008, A Novel Oral BTK Inhibitor For Autoimmune Diseases

04.22.14

Principia Biopharma Secures $50MM Series B Financing

02.13.14

Principia Biopharma Expands Executive Management Team

10.29.12

Principia Biopharma Secures $12.5M Second Tranche In Series A Financing, Expands Senior Management Team


Join our Press Release list

For the latest news on Principia, join our PR email list.